Aeroallergen Sensitization, Serum IgE, and Eosinophilia as Predictors of Response to Omalizumab Therapy during the Fall Season among Children with Persistent Asthma.

[1]  G. Koppelman,et al.  Precision medicine in childhood asthma , 2019, Current opinion in allergy and clinical immunology.

[2]  S. Szefler,et al.  Current State and Future of Biologic Therapies in the Treatment of Asthma in Children. , 2018, Pediatric allergy, immunology, and pulmonology.

[3]  T. Casale,et al.  Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma , 2017, Allergy.

[4]  Achim Zeileis,et al.  Model-Based Recursive Partitioning for Subgroup Analyses , 2016, The international journal of biostatistics.

[5]  P. Gergen,et al.  Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. , 2015, The Journal of allergy and clinical immunology.

[6]  Jeremy Wildfire,et al.  Seasonal risk factors for asthma exacerbations among inner-city children. , 2015, The Journal of allergy and clinical immunology.

[7]  P. Gergen,et al.  Inner city asthma. , 2015, Immunology and allergy clinics of North America.

[8]  S. Walker,et al.  Omalizumab for asthma in adults and children. , 2014, The Cochrane database of systematic reviews.

[9]  S. Spector,et al.  High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. , 2013, The Journal of allergy and clinical immunology.

[10]  W. Busse,et al.  Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. , 2013, American journal of respiratory and critical care medicine.

[11]  P. Gergen,et al.  Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. , 2013, The journal of allergy and clinical immunology. In practice.

[12]  Robert A Silverman,et al.  Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. , 2012, The Journal of allergy and clinical immunology.

[13]  P. Gergen,et al.  Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. , 2011, The New England journal of medicine.

[14]  S. Sullivan,et al.  The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective , 2010, Allergy.

[15]  I. Pavord,et al.  An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. , 2009, American journal of respiratory and critical care medicine.

[16]  D. Postma,et al.  Severe exacerbations predict excess lung function decline in asthma , 2007, European Respiratory Journal.

[17]  J. Bousquet,et al.  Predicting and evaluating response to omalizumab in patients with severe allergic asthma. , 2007, Respiratory medicine.

[18]  Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. , 2007, The Journal of allergy and clinical immunology.

[19]  R. Strunk,et al.  Omalizumab for asthma. , 2006, The New England journal of medicine.

[20]  J Bousquet,et al.  Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE , 2005, Allergy.

[21]  J. Bousquet,et al.  Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. , 2004, Chest.

[22]  Third Expert Panel on theDiagnosis,et al.  Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma , 1997 .